Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection

Sponsor
Birmingham Women's NHS Foundation Trust (Other)
Overall Status
Terminated
CT.gov ID
NCT00566956
Collaborator
(none)
66
1
2
56
1.2

Study Details

Study Description

Brief Summary

· What we know: Hydrosalpinx and IVF About 40% of patients undergoing IVF have tubal disease and in 25%-30% of tubal disease patients there is fluid collection within the tube; hydrosalpinx. The amount of fluid in the hydrosalpinx is known to increase with ovarian stimulation (as in IVF) and often empties into the uterine cavity. Fluid from hydrosalpinges has been found to be detrimental to the growth and development of mouse embryos in vitro, and associated with reduced levels of endometrial integrins in vivo. This could be the explanation of the reduced pregnancy rates after IVF in patients with tubal disease and hydrosalpinx compared with those with tubal disease but no hydrosalpinx. This effect was evidence in both fresh and frozen embryo transfer cycles. Also there was a significant increase in miscarriage in association with hydrosalpinx.

The study aims to answer the question: does ultrasound-guided aspiration of ultrasound diagnosed hydrosalpinx at the time of egg collection improve the pregnancy rate in IVF?

Condition or Disease Intervention/Treatment Phase
  • Procedure: Hydrosalpinx needle aspiration to arm 1
Phase 2

Detailed Description

· What we do not know: Treatment of hydrosalpinx and IVF Several studies in the literature have suggested that the treatment of hydrosalpinx pre-IVF would improve the pregnancy rate to a level similar to tubal disease patients without hydrosalpinx. The treatment modalities explored were salpingectomy, salpingostomy, tubal occlusion and ultrasound-guided aspiration either one month before or at the time of egg collection. All studies reported to date have been retrospective and with poor control design. A prospective randomised controlled trial is needed. All modalities have been associated with a similar improvement in pregnancy rate, but the least invasive modality is ultrasound-guided aspiration at the time of oocyte collection. We propose to conduct a prospective randomised controlled trial to evaluate the effect of ultrasound-guided aspiration (versus no aspiration) of hydrosalpinx at the time of egg collection on the pregnancy rate in IVF.

Study Design

Study Type:
Interventional
Actual Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection Improves Pregnancy Outcome in In-vitro Fertilization: a Randomised Controlled Trial
Study Start Date :
Oct 1, 1999
Actual Study Completion Date :
Jun 1, 2004

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.

Procedure: Hydrosalpinx needle aspiration to arm 1
For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded

No Intervention: 2

Patients assigned to group 2 will not have the hydrosalpinx aspirated

Outcome Measures

Primary Outcome Measures

  1. The primary outcome measures were biochemical (urinary hCG test performed 14 days after embryo transfer) and clinical (presence of gestational sac by transvaginal ultrasound scan) pregnancy rates per randomised women. [2-4 weeks]

Secondary Outcome Measures

  1. Secondary outcome measures were implantation rate, first trimester miscarriages (any pregnancy loss before 12 weeks gestation) and pelvic infection. [2-4 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 39 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • healthy women, ASA class 1 (normal healthy) or class 2 (with mild systemic disease);

  • undergoing IVF or ICSI and reaching the stage of egg collection;

  • with ultrasonically diagnosed hydrosalpinx and identifiable during the phase of ovarian stimulation;

  • giving written informed consent.

Exclusion Criteria:
  • patients not giving written informed consent;

  • patients cancelled for poor ovarian response;

  • ultrasonically diagnosed hydrosalpinx and identifiable for the first time at egg-collection

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assisted Conception Unit, Birmingham Women's Hospital, Birmingham University Birmingham United Kingdom B15 2TG

Sponsors and Collaborators

  • Birmingham Women's NHS Foundation Trust

Investigators

  • Principal Investigator: Nahed Hammadieh, MD,MRCOG, Assisted Conception Unit

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00566956
Other Study ID Numbers:
  • 0288
  • CC/APM/DD/C2/05
First Posted:
Dec 4, 2007
Last Update Posted:
Jul 21, 2015
Last Verified:
Nov 1, 2007
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2015